Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells

Luba Benimetskaya, Johnathan C. Lai, Anastasia Khvorova, Sijian Wu, Emily Hua, Paul Miller, Li Ming Zhang, Cy A. Stein

Research output: Contribution to journalArticle

Abstract

Purpose: Inhibition of the function of Bcl-2 protein has been postulated to sensitize cells to cytotoxic chemotherapy. G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. The aim of the present work is to investigate inhibition of Bcl-2 expression in 518A2 melanoma cells, the cell line on which recent phase II and phase III clinical trials employing this agent were based. Experimental Design: We down-regulated the expression of Bcl-2 protein by two different strategies in these cells: one employing G3139 and controls, and the other using a small interfering RNA approach. Cell viability after treatment with oligonucleotides or small interfering RNA and cytotoxic agents including gemcitibine, DDP, docetaxel, and thapsigargin was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A 518A2 melanoma cell line stably overexpressing Bcl-2 protein was constructed and treated with either these cytotoxic agents or G3139. Results: The cytotoxic effects of either G3139 or small interfering RNA treatment of 518A2 melanoma cells are Bcl-2 independent. In addition, in the Bcl-2-overexpressing cells, only a modest increment in chemoresistance was observed, and treatment with G3139 not only did not down-regulate Bcl-2 expression but produced essentially identical toxicity as was observed in the wild-type or mock-transfected cells. Conclusions: Our results suggest that the mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2. These findings emphasize the nonsequence specific effects of this phosphorothioate oligonucleotide and call into question the validity of Bcl-2 as a target in this cell line.

Original languageEnglish (US)
Pages (from-to)8371-8379
Number of pages9
JournalClinical Cancer Research
Volume10
Issue number24
DOIs
StatePublished - Dec 15 2004

Fingerprint

Melanoma
Pharmaceutical Preparations
Small Interfering RNA
Cytotoxins
docetaxel
Cell Line
Phosphorothioate Oligonucleotides
Phase III Clinical Trials
Proteins
Thapsigargin
Antisense Oligonucleotides
oblimersen
Oligonucleotides
Cell Survival
Research Design
Therapeutics
Down-Regulation
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Benimetskaya, L., Lai, J. C., Khvorova, A., Wu, S., Hua, E., Miller, P., ... Stein, C. A. (2004). Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clinical Cancer Research, 10(24), 8371-8379. https://doi.org/10.1158/1078-0432.CCR-04-1294

Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. / Benimetskaya, Luba; Lai, Johnathan C.; Khvorova, Anastasia; Wu, Sijian; Hua, Emily; Miller, Paul; Zhang, Li Ming; Stein, Cy A.

In: Clinical Cancer Research, Vol. 10, No. 24, 15.12.2004, p. 8371-8379.

Research output: Contribution to journalArticle

Benimetskaya, L, Lai, JC, Khvorova, A, Wu, S, Hua, E, Miller, P, Zhang, LM & Stein, CA 2004, 'Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells', Clinical Cancer Research, vol. 10, no. 24, pp. 8371-8379. https://doi.org/10.1158/1078-0432.CCR-04-1294
Benimetskaya, Luba ; Lai, Johnathan C. ; Khvorova, Anastasia ; Wu, Sijian ; Hua, Emily ; Miller, Paul ; Zhang, Li Ming ; Stein, Cy A. / Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 24. pp. 8371-8379.
@article{6f1b07833beb463f8c17385a95fd4e46,
title = "Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells",
abstract = "Purpose: Inhibition of the function of Bcl-2 protein has been postulated to sensitize cells to cytotoxic chemotherapy. G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. The aim of the present work is to investigate inhibition of Bcl-2 expression in 518A2 melanoma cells, the cell line on which recent phase II and phase III clinical trials employing this agent were based. Experimental Design: We down-regulated the expression of Bcl-2 protein by two different strategies in these cells: one employing G3139 and controls, and the other using a small interfering RNA approach. Cell viability after treatment with oligonucleotides or small interfering RNA and cytotoxic agents including gemcitibine, DDP, docetaxel, and thapsigargin was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A 518A2 melanoma cell line stably overexpressing Bcl-2 protein was constructed and treated with either these cytotoxic agents or G3139. Results: The cytotoxic effects of either G3139 or small interfering RNA treatment of 518A2 melanoma cells are Bcl-2 independent. In addition, in the Bcl-2-overexpressing cells, only a modest increment in chemoresistance was observed, and treatment with G3139 not only did not down-regulate Bcl-2 expression but produced essentially identical toxicity as was observed in the wild-type or mock-transfected cells. Conclusions: Our results suggest that the mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2. These findings emphasize the nonsequence specific effects of this phosphorothioate oligonucleotide and call into question the validity of Bcl-2 as a target in this cell line.",
author = "Luba Benimetskaya and Lai, {Johnathan C.} and Anastasia Khvorova and Sijian Wu and Emily Hua and Paul Miller and Zhang, {Li Ming} and Stein, {Cy A.}",
year = "2004",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1294",
language = "English (US)",
volume = "10",
pages = "8371--8379",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells

AU - Benimetskaya, Luba

AU - Lai, Johnathan C.

AU - Khvorova, Anastasia

AU - Wu, Sijian

AU - Hua, Emily

AU - Miller, Paul

AU - Zhang, Li Ming

AU - Stein, Cy A.

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Purpose: Inhibition of the function of Bcl-2 protein has been postulated to sensitize cells to cytotoxic chemotherapy. G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. The aim of the present work is to investigate inhibition of Bcl-2 expression in 518A2 melanoma cells, the cell line on which recent phase II and phase III clinical trials employing this agent were based. Experimental Design: We down-regulated the expression of Bcl-2 protein by two different strategies in these cells: one employing G3139 and controls, and the other using a small interfering RNA approach. Cell viability after treatment with oligonucleotides or small interfering RNA and cytotoxic agents including gemcitibine, DDP, docetaxel, and thapsigargin was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A 518A2 melanoma cell line stably overexpressing Bcl-2 protein was constructed and treated with either these cytotoxic agents or G3139. Results: The cytotoxic effects of either G3139 or small interfering RNA treatment of 518A2 melanoma cells are Bcl-2 independent. In addition, in the Bcl-2-overexpressing cells, only a modest increment in chemoresistance was observed, and treatment with G3139 not only did not down-regulate Bcl-2 expression but produced essentially identical toxicity as was observed in the wild-type or mock-transfected cells. Conclusions: Our results suggest that the mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2. These findings emphasize the nonsequence specific effects of this phosphorothioate oligonucleotide and call into question the validity of Bcl-2 as a target in this cell line.

AB - Purpose: Inhibition of the function of Bcl-2 protein has been postulated to sensitize cells to cytotoxic chemotherapy. G3139 (Genasense) is a phosphorothioate anti-Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. The aim of the present work is to investigate inhibition of Bcl-2 expression in 518A2 melanoma cells, the cell line on which recent phase II and phase III clinical trials employing this agent were based. Experimental Design: We down-regulated the expression of Bcl-2 protein by two different strategies in these cells: one employing G3139 and controls, and the other using a small interfering RNA approach. Cell viability after treatment with oligonucleotides or small interfering RNA and cytotoxic agents including gemcitibine, DDP, docetaxel, and thapsigargin was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A 518A2 melanoma cell line stably overexpressing Bcl-2 protein was constructed and treated with either these cytotoxic agents or G3139. Results: The cytotoxic effects of either G3139 or small interfering RNA treatment of 518A2 melanoma cells are Bcl-2 independent. In addition, in the Bcl-2-overexpressing cells, only a modest increment in chemoresistance was observed, and treatment with G3139 not only did not down-regulate Bcl-2 expression but produced essentially identical toxicity as was observed in the wild-type or mock-transfected cells. Conclusions: Our results suggest that the mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2. These findings emphasize the nonsequence specific effects of this phosphorothioate oligonucleotide and call into question the validity of Bcl-2 as a target in this cell line.

UR - http://www.scopus.com/inward/record.url?scp=11144220793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144220793&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1294

DO - 10.1158/1078-0432.CCR-04-1294

M3 - Article

C2 - 15623615

AN - SCOPUS:11144220793

VL - 10

SP - 8371

EP - 8379

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -